J
Javier Godino-Ivan Marcos
Publications - 2
Citations - 894
Javier Godino-Ivan Marcos is an academic researcher. The author has contributed to research in topics: Genome-wide association study & Internal medicine. The author has an hindex of 1, co-authored 1 publications receiving 873 citations.
Papers
More filters
Journal ArticleDOI
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24.
Julius Gudmundsson,Patrick Sulem,Andrei Manolescu,Laufey T. Amundadottir,Daniel F. Gudbjartsson,Agnar Helgason,Thorunn Rafnar,Jon Thor Bergthorsson,Bjarni A. Agnarsson,Adam Baker,Asgeir Sigurdsson,Kristrun R. Benediktsdottir,Margret Jakobsdottir,Jianfeng Xu,Thorarinn Blondal,Jelena Kostic,Jielin Sun,Shyamali Ghosh,Simon N. Stacey,Magali Mouy,Jona Saemundsdottir,Valgerdur M Backman,Kristleifur Kristjansson,Alejandro Tres,Alan W. Partin,Marjo T Albers-Akkers,Javier Godino-Ivan Marcos,Patrick C. Walsh,Dorine W. Swinkels,Sebastian Navarrete,Sarah D. Isaacs,Katja K.H. Aben,Theresa Graif,John Cashy,M. Ruiz-Echarri,Kathleen E. Wiley,Brian K. Suarez,J. Alfred Witjes,Mike Frigge,Carole Ober,Eirikur Jonsson,Gudmundur V. Einarsson,Jose I. Mayordomo,Lambertus A. Kiemeney,William B. Isaacs,William J. Catalona,Rosa B. Barkardottir,Jeffrey R. Gulcher,Unnur Thorsteinsdottir,Augustine Kong,Kari Stefansson +50 more
TL;DR: A second genetic variant in the 8q24 region that, in conjunction with another variant recently discovered, accounts for about 11%–13% of prostate cancer cases in individuals of European descent and 31% of cases in African Americans is reported.
Journal ArticleDOI
Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe COVID-19: The PANCOVID Randomized Clinical Trial
Rocio Montejano,F. de la Calle-Prieto,María Velasco,Carlos Guijarro,J. Queiruga-Parada,M.C. Jiménez-González,P González-Ruano,Patricia Martínez,Ane Josune Goikoetxea,Marta Ibarrola,Mar Ciudad,Ángela Gutiérrez,Miguel Torralba,A. Díaz-Brasero,Pablo Ryan,Cristina Marcelo,Cristina Diez,Sofía Ibarra,Esperanza Merino,Vicente Estrada,Javier Godino-Ivan Marcos,Maria Teresa Novella,M. A. Rivera,Manuel Ruiz-Muñoz,M. de Miguel,Llanos Soler,Mikel Del Álamo,Santiago Moreno,Antonio J. Carcas,Alberto M. Borobia,Jose R. Arribas +30 more
TL;DR: The trial was stopped before reaching planned sample size due to the decrease in the number of cases and a mortality rate substantially lower than expected and the results do not suggest a beneficial effect of TDF/FTC; nevertheless, they are compatible with thebeneficial effect of baricitinib already established by other clinical trials.